Asia: Market for Human Blood And Animal Blood Prepared For Therapeutic, Pophylactic Or Diagnostic Uses 2022

Market Size for Human Blood And Animal Blood Prepared For Therapeutic, Pophylactic Or Diagnostic Uses in Asia

In 2021, the Asian human and animal blood market decreased by -X% to $X for the first time since 2015, thus ending a five-year rising trend. The total consumption indicated strong growth from 2012 to 2021: its value increased at an average annual rate of +X% over the last nine-year period. The trend pattern, however, indicated some noticeable fluctuations being recorded throughout the analyzed period. Based on 2021 figures, consumption increased by +X% against 2012 indices. The level of consumption peaked at $X in 2020, and then dropped slightly in the following year.

Production of Human Blood And Animal Blood Prepared For Therapeutic, Pophylactic Or Diagnostic Uses in Asia

In value terms, human and animal blood production reduced slightly to $X in 2021 estimated in export price. The total production indicated a buoyant increase from 2012 to 2021: its value increased at an average annual rate of +X% over the last nine-year period. The trend pattern, however, indicated some noticeable fluctuations being recorded throughout the analyzed period. Based on 2021 figures, production increased by +X% against 2013 indices. The most prominent rate of growth was recorded in 2016 with an increase of X% against the previous year. Over the period under review, production hit record highs at $X in 2020, and then shrank in the following year.

Exports of Human Blood And Animal Blood Prepared For Therapeutic, Pophylactic Or Diagnostic Uses

Exports in Asia

In 2021, overseas shipments of human blood and animal blood prepared for therapeutic, pophylactic or diagnostic uses were finally on the rise to reach X tons after two years of decline. In general, exports enjoyed buoyant growth. The volume of export peaked at X tons in 2018; afterwards, it flattened through to 2021.

In value terms, human and animal blood exports rose sharply to $X in 2021. Over the period under review, exports posted a strong increase. The pace of growth was the most pronounced in 2018 with an increase of X% against the previous year. The level of export peaked in 2021 and is likely to see steady growth in years to come.

Exports by Country

The shipments of the five major exporters of human blood and animal blood prepared for therapeutic, pophylactic or diagnostic uses, namely India, China, Turkey, South Korea and Jordan, represented more than two-thirds of total export. Iran (X tons) held a X% share (based on physical terms) of total exports, which put it in second place, followed by Hong Kong SAR (X%).

From 2012 to 2021, the most notable rate of growth in terms of shipments, amongst the leading exporting countries, was attained by Iran (with a CAGR of +X%), while the other leaders experienced more modest paces of growth.

In value terms, South Korea ($X) remains the largest human and animal blood supplier in Asia, comprising X% of total exports. The second position in the ranking was held by China ($X), with a X% share of total exports. It was followed by India, with a X% share.

From 2012 to 2021, the average annual rate of growth in terms of value in South Korea amounted to +X%. In the other countries, the average annual rates were as follows: China (+X% per year) and India (+X% per year).

Export Prices by Country

The export price in Asia stood at $X per ton in 2021, with a decrease of -X% against the previous year. Overall, the export price, however, saw a strong expansion. The pace of growth was the most pronounced in 2019 an increase of X% against the previous year. Over the period under review, the export prices hit record highs at $X per ton in 2020, and then contracted markedly in the following year.

Prices varied noticeably by the country of origin: the country with the highest price was South Korea ($X per ton), while Iran ($X per ton) was amongst the lowest.

From 2012 to 2021, the most notable rate of growth in terms of prices was attained by China (+X%), while the other leaders experienced more modest paces of growth.

Imports of Human Blood And Animal Blood Prepared For Therapeutic, Pophylactic Or Diagnostic Uses

Imports in Asia

In 2021, the amount of human blood and animal blood prepared for therapeutic, pophylactic or diagnostic uses imported in Asia skyrocketed to X tons, picking up by X% against 2020 figures. In general, imports saw a buoyant increase. The pace of growth was the most pronounced in 2017 with an increase of X% against the previous year. Over the period under review, imports attained the peak figure in 2021 and are expected to retain growth in years to come.

In value terms, human and animal blood imports skyrocketed to $X in 2021. Overall, imports recorded a prominent expansion. The pace of growth appeared the most rapid in 2017 when imports increased by X%. Over the period under review, imports attained the maximum in 2021 and are expected to retain growth in years to come.

Imports by Country

In 2021, China (X tons), Saudi Arabia (X tons) and Malaysia (X tons) was the key importer of human blood and animal blood prepared for therapeutic, pophylactic or diagnostic uses in Asia, creating X% of total import. India (X tons) held the next position in the ranking, followed by Japan (X tons), Vietnam (X tons) and Turkey (X tons). All these countries together held approx. X% share of total imports. Thailand (X tons), South Korea (X tons), Singapore (X tons), Kazakhstan (X tons), the United Arab Emirates (X tons) and the Philippines (X tons) followed a long way behind the leaders.

From 2012 to 2021, the most notable rate of growth in terms of purchases, amongst the leading importing countries, was attained by Vietnam (with a CAGR of +X%), while imports for the other leaders experienced more modest paces of growth.

In value terms, China ($X) constitutes the largest market for imported human blood and animal blood prepared for therapeutic, pophylactic or diagnostic uses in Asia, comprising X% of total imports. The second position in the ranking was held by Japan ($X), with a X% share of total imports. It was followed by Saudi Arabia, with an X% share.

From 2012 to 2021, the average annual rate of growth in terms of value in China amounted to +X%. The remaining importing countries recorded the following average annual rates of imports growth: Japan (+X% per year) and Saudi Arabia (+X% per year).

Import Prices by Country

In 2021, the import price in Asia amounted to $X per ton, rising by X% against the previous year. Over the period under review, the import price continues to indicate a relatively flat trend pattern. The growth pace was the most rapid in 2020 when the import price increased by X%. The level of import peaked at $X per ton in 2018; however, from 2019 to 2021, import prices failed to regain momentum.

Prices varied noticeably by the country of destination: the country with the highest price was Japan ($X per ton), while Malaysia ($X per ton) was amongst the lowest.

From 2012 to 2021, the most notable rate of growth in terms of prices was attained by South Korea (+X%), while the other leaders experienced more modest paces of growth.

Source: IndexBox Platform

Frequently Asked Questions (FAQ) :